Literature DB >> 2940973

Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.

D H Pitkin, B A Mico, R D Sitrin, L J Nisbet.   

Abstract

The pharmacokinetics and urinary excretion of nine glycopeptide antibiotics with diverse pIs (3.8 to 8.5) and lipophilicities were studied. The disposition of the aridicin antibiotics and their hydrolysis products were examined in male CD-1 mice after subcutaneous and intravenous administration and compared with the disposition of teicoplanin, ristocetin, and vancomycin. The total systemic clearance, half-life, volume of distribution, and urinary excretion were highly correlated with pIs. In general, as the pI decreased, the clearance, urinary recovery, and volume of distribution decreased, whereas the half-life increased. With those glycopeptides that had similar pIs, clearance decreased and half-life increased with increasing lipophilicity. The urinary recovery of the glycopeptides decreased with decreasing pI and increasing lipophilicity. Because vancomycin (pI = 8.0) is cleared by glomerular filtration, increased binding to serum is the likely mechanism of reduced renal clearance for glycopeptides with low pIs. These results are consistent with previous findings concerning the correlation of physical-chemical properties and the drug disposition of small organic molecules. Results of these studies also indicate that desirable pharmacokinetic properties can be incorporated into glycopeptides through semisynthetic modifications.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940973      PMCID: PMC180410          DOI: 10.1128/AAC.29.3.440

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics of teicoplanin in man after intravenous administration.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

3.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

4.  Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships.

Authors:  J K Seydel; D Trettin; H P Cordes; O Wassermann; M Malyusz
Journal:  J Med Chem       Date:  1980-06       Impact factor: 7.446

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

7.  Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products.

Authors:  A Malabarba; P Strazzolini; A Depaoli; M Landi; M Berti; B Cavalleri
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

8.  Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.

Authors:  P H Hinderling; O Schmidlin; J K Seydel
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

9.  Structure-pharmacokinetic relationships among the barbiturates in the rat.

Authors:  S Toon; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

10.  Antimicrobial activity of aridicins, novel glycopeptide antibiotics with high and prolonged levels in blood.

Authors:  S F Grappel; A J Giovenella; L Phillips; D H Pitkin; L J Nisbet
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

View more
  5 in total

1.  Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin.

Authors:  Evelien Vanderlinden; Els Vanstreels; Eline Boons; Wouter ter Veer; Anke Huckriede; Dirk Daelemans; Alfons Van Lommel; Erzsébet Rőth; Ferenc Sztaricskai; Pàl Herczegh; Lieve Naesens
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

2.  Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum.

Authors:  R W Wittendorf; J E Swagzdis; R Gifford; B A Mico
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

3.  Pharmacokinetics of individual components of teicoplanin in man.

Authors:  A Bernareggi; A Danese; A Cometti; G Buniva; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

4.  Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.

Authors:  W R Outman; C H Nightingale; K R Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers.

Authors:  P L Carver; C H Nightingale; R Quintiliani; K Sweeney; R C Stevens; E Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.